Cardiovascular Disease Prevention
HI NENC is delivering a Cardiovascular Disease (CVD) Prevention programme, nationally mandated by NHS England. The programme supports CVD Prevention across the North East and North Cumbria with a particular focus on chronic kidney disease (CKD), disordered lipids, familial hypercholesterolaemia (FH) and hypertension. The other clinical area includes atrial fibrillation (AF) which is legacy work from a previous national programme.
Aims of the CVD Prevention Programme
By collaboratively working with partners, we aim to reduce cardiovascular events for patients as a result of their CVD risk factors, closing health inequality gaps, and improving their health by reducing morbidity and mortality.
Our mission is to ensure patients with CVD risk factors are detected and treated appropriately, and to ensure legacy work from the recent national CVD programmes are sustained.
This will be achieved through collaborative working with the regional health and social care system, to reduce inequalities within our population, providing capability and capacity to meet our objectives.
Benefits
- Prevention of future cardiovascular events, increasing years of wellness.
- Supporting PCNs to achieve their QOF 2024/25.
- Supporting ambitions laid out in the NHS Long Term Plan.
- Increase awareness of patients & clinicians of CKD as a risk factor for CVD.
- Increase awareness of patients & clinicians around the common genetic condition, FH.
Programme Delivery
The programme will be delivered in its constituent parts, but, as far as we are able, we will be taking a multi-morbid approach focusing on a cardio-renal-metabolic (CaReMe) ethos. For more information on the different elements please click on the appropriate topic in which you are interested.
The programme has a strategy group consisting of key stakeholders from across NENC, who provide support, insight and challenge to enable the programme to be responsive and accountable.
Metrics
Programme metrics have been developed for CKD, lipids, FH and hypertension. Success of the programme, however, will depend both on opportunistic and systematic case finding of eligible patients through innovative and validated CVD search tools such as CDRC, cascade testing, and robust primary and secondary CVD prevention pathway implementation, all seeking to optimise patients’ management of lipids, hypertension and CKD regardless of which setting their care is delivered in.
NEQOS lead on measurement support for HI NENC Population Health Improvement Programmes. This involves presenting data to the HI NENC strategy group. The latest presentation can be seen on the link below.
Feedback from local partners
Barry Todd is a North East Pharmacist Practitioner and the Pharmacy Lead at Wallsend Primary Care Network, who has working in partnership with HI NENC to deliver the programme. He said:
“In the 42 years I’ve been a Pharmacist, I’ve never been so excited at the opportunity of breaking down barriers and being able to work collaboratively across all sectors.
“Together we are making a real difference in tackling health care inequalities and driving down cardiovascular morbidity and mortality.”
See details of our partnership working in our case studies and joint working agreements below.
Lipid-lowering Therapy – A Pharmacist-led Clinic for Secondary Prevention Vascular and Diabetic Foot Patients
Newcastle Hospitals NHS Foundation Trust and HI NENC have setup a new clinic to provide targeted treatment and support to vascular and diabetic foot patients, who have had a cardiovascular event such as a heart attack or stroke.
The pharmacist-led clinic, set up by Matthew Hart, Specialist Clinical Pharmacist, is thought to be the first of its kind in the UK.
HI NENC has funded Matthew to run the clinic two days a week and provided support with statistical analysis.
Educating healthcare professionals about familial hypercholesterolaemia: from a local University to a national Massive Open Online Course (MOCC
The NHS long term plan highlighted the need to improve the identification and management of with familial hypercholesterolaemia, driving a need for further training for healthcare professionals.
Health Innovation Network funded a five week course for healthcare professionals, led by Health Innovation North East and North Cumbria. The course was developed and delivered to 118 delegates by Northumbria University and a panel of experts in FH.
Due to high demand for the course, a Massive Open Online Course (MOCC) has been developed. The course equips healthcare professionals across the country to better identify and support people with FH. The course is free and can be accessed here.
Improving access to FH Genetic Testing: GENinCode
Familial hypercholesterolaemia (FH) is a preventable genetic disease which causes high levels of cholesterol in the blood. Yet, the condition remains underdiagnosed in England, with only 5.8% of cases identified. The NHS Long Term Plan set a goal to identify 25% of FH patients and introduced measures like a national cardiovascular disease audit and a Primary Care Network (PCN) directive for systematic case finding. However, genetic testing, the gold standard for FH diagnosis, faces capacity constraints within England’s Genomic Laboratory Hubs, leading to long waiting lists in lipid clinics.
To address this, Health Innovation North East and North Cumbria (HI NENC), in partnership with GENinCode, piloted an alternative genetic testing approach. This programme demonstrated cost-effective, efficient testing with faster reporting times, potentially enhancing identification rates and supporting the NHS goal of improved FH management and prevention.
CVD healthy heart check pathway using PocDoc® rapid lipid testing
PocDoc® is an innovative point-of-care device delivering a 5-marker lipid panel result in just eight minutes via a smartphone or tablet app. This innovation enables faster detection of cardiovascular disease (CVD) markers, such as those linked to heart attacks and strokes, in non-clinical settings.
HI NENC collaborated with PocDoc to evaluate the device in a real-world setting. This included cholesterol testing at home and in community venues, targeting deprived communities and removing barriers to traditional health checks. 10,000 tests were available during the pilot phase to dramatically expand access to testing, with an aim to identify at-risk individuals early and prevent more cases of CVD.
HI NENC works collaboratively with a number of partners to enhance local services, please see details of our joint working agreements below.
Sanofi and HI NENC are working in partnership under a joint working agreement to facilitate better identification of patients within primary care who may be at risk of having Familial Hypercholesterolaemia (FH) or high cardiovascular risk. Read in full in this joint working agreement.
Optimising Lipid Management
The HI NENC Cardiovascular Disease Prevention Programme has a particular focus on optimising the treatment of disordered lipids to give patients the best chance of avoiding cardiac events. Disordered Lipids Disordered lipids impact peoples’ health over time causing heart attack and strokes….
CVD resources for healthcare professionals
Cardiovascular disease (CVD) prevention resources for healthcare professionals in the North East and North Cumbria
CVD events and latest news
The Cardiovascular Disease Prevention Team send out a regular newsletter and hold a number of events and training opportunities for healthcare professionals working in the North East and North Cumbria. Find out more about the latest news and upcoming events…
Familial Hypercholesterolaemia
The HI NENC Cardiovascular Disease Prevention Programme includes Familial Hypercholesterolaemia (FH), identifying people with this genetic condition and optimising their treatment to give patients the best chance of avoiding cardiac events. HI NENC has developed resources to support practices across…
Lipid Management Pathway
The HI NENC Cardiovascular Disease Prevention Programme has a focus on reducing patients’ overall cardiovascular risk, which includes the optimisation of lipids, to provide the best opportunity of avoiding further cardiac events. This page has been created to provide information to…
Blood Pressure Optimisation
The management of hypertension remains a key element of HI NENC’s CVD Prevention Programme. HI NENC, working in collaboration with NENC ICB, is delivering a ‘back to basics’ education programme to healthcare professionals working in and supporting primary care in…
Chronic Kidney Disease
As part of the wider Cardiovascular Disease Prevention Programme, HI NENC is delivering a Chronic Kidney Disease (CKD) programme. The CKD programme will focus on improving earlier diagnosis and supporting early medical treatment of people with CKD to slow disease progression…
Cholesterol testing pilot
As part of a wider Cardiovascular Disease Prevention Programme, HI NENC delivered pilot programme trialling innovative cholesterol test, PocDoc. The pilot came to an end in June 2024 and is currently undergoing an evaluation. Aim The aim of the pilot…
Atrial Fibrillation
The Atrial Fibrillation (AF) programme, which ran as a national programme from 2018-2020, led to the development of several valuable resources. In addition, one key project from this work continues to operate as a legacy project. Legacy project HI NENC…
Innovation for Healthcare Inequalities Programme (InHIP)
The Innovation for Healthcare Inequalities Programme (InHIP) was a national programme. The programme officially ended in April 2024 however HI NENC is continuing this work through a Healthy Heart Checks programme. More information coming soon. HI NENC led on the…